Cheers mate. I would genuinely appreciate anything you have to...

Cheers mate. I would genuinely appreciate anything you have to offer. One of the reasons I like IIQ is due to some of the people involved and the vision I think that the Polynovo chairman David Williams and Merchant Opportunities Fund, Andrew Chapman (both long term major shareholders) have to build a leading Aussie biotech. I like the commentary Williams and Chapman have said before about lots of potential aussie biotechs dying by a thousand lashes (ie lack of funding) and many great potential success stories fail due to this. My interpretation of their views (gained from listening/reading lots of their interviews), is that they see an opportunity to make the most of the significant potential we have in Australia in this biotech space. They have said they want to build a company which has the ability to harness and support the great work done in the universities and research labs which otherwise would not make it to commercialization due to a lack of ability to navigate the hurdles and run out of funding. I feel their stated/interpreted strategy is on display when you look at the evolution of Bard1 and Sienna into IIQ as follows:

• Getting a hands on board to ensure the business has the governance and experience to survive - Max Johnson (check out his resume) and Philip Powell (and their involvement in the success of PNV over 10 years - a genuinely credible Aussie success story and business). Powell retired from PNV approx 12 months ago but was there for many years.
• Brining great tech together - witness the merger of Sienna (SubB2M) and Bard1 (AAB tech) and acquisition of the Exonet tech (Williams and Chapman were major shareholder of both of these companies prior to the merger and remain so in IIQ now).
• Collaborating with great research institutions - witness the collaborations they have in place with Uni of Queensland, Adelaide Uni, Griffiths Uni, Minomic and one other small biotech whose name escapes me as some examples...
• Bringing the right expertise together - witness the credentials of the new senior leadership team they have put together =-Dr Greg Rice, Dr Wayne Jensen, Dr Emily Stein, and Susan Belzer - all relatively new team members.
• Finally, ensuring the business is funded adequately - not entirely sure how I prove this but I think it is possible they may get to reasonable commercialisation with the 10 quarters of funding they have left based on their road map ( worst case scenario no more than 1 more cash raising).

For me, being a clapped out miner with a small brain, I've struggled to get my head around the technology in great detail but from a superficial level 100% Sensitivity and specificity for all stages ovarian and similar for breast looks pretty impressive as does the exonet.
Lets share what we can for the benefit of all of us average Joes and Joannes.
cheers mate.